Table 3.
Univariate analyses of PFS.
| Univariate analyses | Multivariate analyses | ||||
|---|---|---|---|---|---|
| Parameter | PFS | Adjusted HR (95% CI) | p- value* | Adjusted HR (95% CI) | p- value* |
| Age | 0.143 | ||||
| ≤70 | 2.400 | 1.604 | |||
| >70 | 1.967 | (0.852-3.018) | |||
| Sex | 0.814 | ||||
| Male | 2.800 | 1.044 | |||
| Female | 2.100 | (0.729-1.496) | |||
| PS (ECOG) | 0.908 | ||||
| 0 | 1.933 | 0.960 | |||
| 1-2 | 2.533 | (0.480-1.919) | |||
| Primary tumor location | 0.042 | 0.012 | |||
| Left | 2.567 | 1.519 | 1.709 | ||
| Right | 1.933 | (1.016-2.270) | (1.127-2.592) | ||
| KRAS | 0.280 | ||||
| Wild | 2.800 | 1.237 | |||
| Mutant | 1.967 | (0.841-1.822) | |||
| No. of Metastatic sites | 0.037 | 0.011 | |||
| ≤1 | 2.533 | 1.523 | 1.705 | ||
| >2 | 1.933 | (1.025-2.261) | (1.132-2.566) | ||
| Previous anti-VEGF treatment | 0.041 | ||||
| NO | 2.833 | 1.720 | |||
| YES | 2.233 | (1.023-2.894) | |||
| Previous anti-EGFR treatment | 0.605 | ||||
| NO | 2.367 | 0.908 | |||
| YES | 2.633 | (0.630-1.309) | |||
| Number of previous systemic anticancer therapies | 0.285 | ||||
| ≤3 | 2.100 | 0.823 | |||
| 3> | 2.400 | (0.576-1.176) | |||
* Univariate and multivariate analysis to identify the significant, independent, prognostic factors of various clinical parameters for survival is calculated by Cox proportional hazards regression model.